TriSalus Life Sciences (TLSI) Research & Development (2022 - 2026)

TriSalus Life Sciences' Research & Development history runs 5 years deep, the most recent figure standing at $7.4 million for Q1 2026.

• On a quarterly basis, Research & Development rose 10.08% year-over-year to $7.4 million in Q1 2026; TTM through Mar 2026 was $12.4 million, a 55.81% decrease from a year earlier, with the FY2025 full-year figure at $15.0 million, down 42.08% from the prior year.
• Research & Development grew to $7.4 million in Q1 2026 per TLSI's latest filing, from -$5.8 million in the prior quarter.
• Across five years, Research & Development topped out at $12.5 million in Q4 2022 and bottomed at -$5.8 million in Q4 2025.
• The 5-year median for Research & Development is $6.0 million (2024), against an average of $5.9 million.
• Across the five-year window, Research & Development jumped 213.73% in 2023 and slumped 151.94% in 2025, its largest moves.
• Year by year, Research & Development stood at $12.5 million in 2022, then sank by 37.73% to $7.8 million in 2023, then surged by 43.0% to $11.1 million in 2024, then plunged by 151.94% to -$5.8 million in 2025, then jumped by 228.45% to $7.4 million in 2026.
• Per Business Quant, the three latest TLSI Research & Development figures stand at $7.4 million (Q1 2026), -$5.8 million (Q4 2025), and $6.8 million (Q3 2025).